Atrys Health, S.A. acquired Significant Impact Systems SL from Nexxus Iberia Private Equity Fund I, FCR, a fund managed by Nexxus Iberia SGEIC S.A. for €94.47 million.
June 12, 2022
Share
Atrys Health, S.A. (BME:ATRY) agreed to acquire Significant Impact Systems SL from Nexxus Iberia Private Equity Fund I, FCR, a fund managed by Nexxus Iberia SGEIC S.A. for €94.47 million on June 13, 2022. Consideration of €72.1 million will be paid in cash and €4.27 million will be paid in kind through the distribution of Atrys shares. In addition, a contingent earn-out price of approximately € 18.1 million has been agreed upon, subject to the EBITDA Bienzobas reaches in 2022. The acquisition will be financed by Atrys through equity in an accelerated bookbuild offering solely aimed at qualified domestic and foreign investors. Bienzobas recorded a turnover of €30.62 million in 2021. Inmaculada Castello, Guillermo Guerra, Irene Medina de Alba, Emiliano Moreno and Jacobo Palanca Reh of Gómez-Acebo & Pombo Abogados, S.L.P. acted as legal advisor to Atrys Health, S.A. (BME:ATRY). Inmaculada Castelló of Pinsent Masons acted as legal advisor to Atrys Health, S.A. (BME:ATRY). EY Abogados acted as legal advisor to Nexxus Iberia SGEIC S.A.. Mediobanca Banca di Credito Finanziario S.p.A. (BIT:MB) acted as financial advisor to Atrys Health, S.A. (BME:ATRY).
Atrys Health, S.A. (BME:ATRY) completed the acquisition of Significant Impact Systems SL from Nexxus Iberia Private Equity Fund I, FCR, a fund managed by Nexxus Iberia SGEIC S.A. on June 13, 2022.
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
Atrys Health, S.A. acquired Significant Impact Systems SL from Nexxus Iberia Private Equity Fund I, FCR, a fund managed by Nexxus Iberia SGEIC S.A. for €94.47 million.
ATRYS HEALTH, S.A. 
